International Journal of Pharmacy and Pharmaceutical Research (IJPPR)
Volume 32, Issue 4, April 2026 ijppr.humanjournals.com ISSN: 2349-7203

# Oral Colon-Specific Drug Delivery Approaches in Inflammatory Bowel Disease: From Conventional Systems to Nanotechnology

**Miss. Sheetal Singh, Prof (Dr.) Arpita Singh, Miss. Anupama Maurya**

Department of Pharmaceutics, Seth Vishambhar Nath Institute of Pharmacy, India.

Received: 19 February 2026 Revised: 28 February 2026 Accepted: 20 March 2026

**ABSTRACT**

Inflammatory Bowel Disease (IBD), encompassing Crohn's disease and ulcerative colitis, is a chronic inflammatory disorder of the gastrointestinal tract requiring targeted and sustained drug delivery for effective management. Oral colon-specific drug delivery systems have gained significant attention due to their ability to localize therapeutic agents directly at the site of inflammation, thereby enhancing efficacy and minimizing systemic side effects. Conventional approaches, including pH-dependent, time-dependent, and microbially triggered systems, have been widely explored but often suffer from limitations such as variable gastrointestinal transit time and unpredictable drug release. Recent advancements in nanotechnology have revolutionized colon-targeted drug delivery by offering improved precision, stability, and controlled release profiles. Nanocarriers such as nanoparticles, liposomes, dendrimers, and polymeric micelles enable enhanced mucosal adhesion, targeted drug accumulation, and protection of labile drugs from degradation in the upper gastrointestinal tract. Additionally, these systems can be engineered to respond to specific physiological triggers within the colon, including enzymatic activity and inflammatory markers. This review highlights the evolution of oral colon-specific drug delivery systems from conventional strategies to advanced nanotechnological approaches. It also discusses the challenges, current research trends, and future perspectives in optimizing targeted therapy for IBD. The integration of nanotechnology with traditional delivery systems holds promising potential for improving therapeutic outcomes and patient compliance in the management of IBD.

**Keywords:** Inflammatory Bowel Disease (IBD), Crohn's disease, ulcerative colitis, Colon-specific drug delivery, Oral drug delivery systems, pH-dependent systems, Time-dependent systems, Microbially triggered systems

## .1. INTRODUCTION

Inflammatory Bowel Disease (IBD) is a chronic, immune-mediated disorder of the gastrointestinal (GI) tract that encompasses two major clinical entities: Crohn's disease and ulcerative colitis. These disorders are characterized by persistent inflammation, unpredictable periods of remission and relapse, and a progressive course that can significantly impair a patient's quality of life. Over the past few decades, the global burden of IBD has increased markedly, especially in rapidly developing regions such as India. This rise has been attributed to westernization of lifestyle, changes in dietary patterns (high-fat, low-fiber diets), increased antibiotic use, environmental pollution, and improved diagnostic capabilities.

The pathogenesis of IBD is highly complex and multifactorial, involving an intricate interplay between genetic susceptibility, environmental factors, intestinal microbiota, and immune system dysregulation. Genetically predisposed individuals exhibit an abnormal immune response to the intestinal microbiota. Genome-wide association studies have identified numerous susceptibility genes, such as NOD2, ATG16L1, and IL23R, which are involved in immune regulation, autophagy, and microbial recognition. However, genetic predisposition alone is insufficient to cause disease; environmental triggers play a crucial role in initiating and perpetuating inflammation.

One of the central features of IBD pathophysiology is immune dysregulation. In a healthy individual, the intestinal immune system maintains a delicate balance between tolerance to commensal bacteria and defense against pathogens. In IBD, this balance is disrupted, leading to an exaggerated immune response. This involves activation of T-helper cells (Th1, Th2, and Th17 subsets), overproduction of pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNF-α), interleukins (IL-1, IL-6, IL-17), and interferon-gamma. These mediators promote chronic inflammation, tissue injury, and recruitment of additional immune cells, creating a self-sustaining inflammatory cycle.

Another critical component in IBD is the alteration of gut microbiota, often referred to as dysbiosis. The human gut contains trillions of microorganisms that play essential roles in digestion, metabolism, and immune function. In IBD patients, there is a reduction in beneficial bacteria (such as Firmicutes) and an increase in potentially harmful bacteria (such as Proteobacteria). This imbalance can compromise the intestinal barrier, allowing bacterial antigens to penetrate the mucosa and trigger immune responses. Additionally, microbial metabolites such as short-chain fatty acids, which normally have anti-inflammatory effects, are reduced in IBD.

The integrity of the intestinal epithelial barrier is also compromised in IBD. Normally, tight junctions between epithelial cells prevent the passage of harmful substances from the gut lumen into the bloodstream. In IBD, these tight junctions become disrupted, leading to increased intestinal permeability, commonly referred to as "leaky gut." This allows luminal antigens, toxins, and bacteria to enter the mucosa, further exacerbating inflammation.

Crohn's disease is characterized by transmural inflammation, meaning that the inflammation extends through all layers of the intestinal wall. It can affect any part of the GI tract, from the mouth to the anus, although it most commonly involves the terminal ileum and colon. The disease is often discontinuous, with "skip lesions" where areas of diseased tissue are interspersed with healthy segments. This transmural nature predisposes patients to complications such as strictures (narrowing of the intestine due to fibrosis), fistulas (abnormal connections between different parts of the intestine or between the intestine and other organs), and abscess formation.

In contrast, ulcerative colitis is limited to the colon and rectum and involves only the mucosal and submucosal layers. The inflammation is continuous, starting from the rectum and extending proximally in a uniform manner. Ulcerative colitis primarily causes ulceration of the mucosal lining, leading to symptoms such as bloody diarrhea and tenesmus (a sensation of incomplete evacuation). Although it does not typically cause fistulas or strictures, long-standing ulcerative colitis is associated with an increased risk of colorectal cancer due to chronic inflammation and epithelial dysplasia.

Clinically, both conditions present with a range of gastrointestinal and systemic symptoms. Common manifestations include abdominal pain, chronic diarrhea, rectal bleeding, weight loss, fatigue, and reduced appetite. Extraintestinal manifestations are also common and can affect the skin (erythema nodosum), joints (arthritis), eyes (uveitis), and liver (primary sclerosing cholangitis). These systemic features highlight the fact that IBD is not merely a localized intestinal disease but a systemic inflammatory condition.

If left untreated or poorly managed, IBD can lead to severe complications. In Crohn's disease, chronic inflammation can result in fibrosis and intestinal obstruction due to strictures. Fistula formation can lead to significant morbidity, especially when involving the perianal region. In ulcerative colitis, complications include severe bleeding, toxic megacolon (a life-threatening dilation of the colon), and an increased risk of colorectal cancer. The risk of cancer increases with the duration and extent of disease, making regular surveillance colonoscopy essential in long-term management. BD represents a complex and multifaceted disease involving immune dysregulation, genetic factors, microbial imbalance, and environmental influences. The differences in pathological features between Crohn's disease and ulcerative colitis are critical for diagnosis and treatment planning. Understanding these underlying mechanisms is essential for developing targeted therapeutic strategies, including advanced drug delivery systems such as colon-specific and nanotechnology-based approaches, which aim to improve treatment efficacy and reduce systemic side effects.

**Table 1: Comparison Between Crohn's Disease and Ulcerative Colitis**

| Feature | Crohn's Disease | Ulcerative Colitis |
|---|---|---|
| Location | Entire GI tract (mouth to anus) | Colon and rectum only |
| Pattern | Skip lesions (discontinuous) | Continuous inflammation |
| Depth of inflammation | Transmural (all layers) | Mucosal and submucosal |
| Common symptoms | Abdominal pain, weight loss | Bloody diarrhoea, rectal bleeding |
| Complications | Fistula, strictures, abscess | Toxic megacolon, colorectal cancer |
| Histology | Granulomas present | No granulomas |

### 1.1 Need for Targeted Drug Delivery in IBD

Inflammatory Bowel Disease (IBD), including Crohn's disease and ulcerative colitis, requires long-term and often lifelong pharmacological management. The primary therapeutic goals in IBD are to induce remission during active disease, maintain remission, prevent complications, and improve the overall quality of life of patients. Conventional pharmacotherapy has been the mainstay of treatment; however, it is associated with several limitations that highlight the urgent need for targeted drug delivery systems.

### 1.2 Limitations of Conventional Drug Therapy

The conventional treatment of IBD involves various classes of drugs such as aminosalicylates (e.g., mesalamine), corticosteroids (e.g., prednisolone), immunosuppressants (e.g., azathioprine), and biologics (e.g., anti-TNF agents like infliximab). Although these drugs are effective in controlling inflammation and symptoms, their therapeutic success is often limited by non-specific drug distribution throughout the body.

When administered orally or systemically, these drugs are absorbed into the bloodstream and distributed to both diseased and healthy tissues. This lack of selectivity leads to several systemic adverse effects. For example, prolonged use of corticosteroids can cause osteoporosis, hypertension, hyperglycemia, and increased susceptibility to infections. Similarly, immunosuppressants may lead to bone marrow suppression and increased risk of malignancies, while biologics can predispose patients to serious infections and immune reactions.

Another critical limitation is that many drugs used in IBD therapy are either degraded in the upper gastrointestinal (GI) tract or absorbed before reaching the colon. The stomach's acidic environment and the presence of digestive enzymes can degrade sensitive drug molecules, particularly proteins and peptides. As a result, only a small fraction of the administered dose reaches the colon, which is the primary site of inflammation in most IBD cases. This leads to reduced therapeutic efficacy and necessitates higher doses, further increasing the risk of side effects.

**Table 2: Conventional Drugs Used in IBD**

| Drug Class | Examples | Mechanism of Action | Limitations |
|---|---|---|---|
| Aminosalicylates | Mesalamine, Sulfasalazine | Anti-inflammatory (inhibits prostaglandins) | Limited efficacy in severe cases |
| Corticosteroids | Prednisolone, Budesonide | Suppress immune response | Systemic side effects (long-term use) |
| Immunosuppressants | Azathioprine, Methotrexate | Inhibit immune cell proliferation | Risk of infections, toxicity |
| Biologics | Infliximab, Adalimumab | Anti-TNF action | Expensive, immunogenicity |

### 1.3 Importance of Colon as a Target Site

The colon plays a central role in the pathophysiology of IBD, especially in ulcerative colitis, where inflammation is confined to the colon and rectum. Even in Crohn's disease, the colon is frequently involved. Therefore, delivering drugs directly to the colon offers a rational and effective strategy for disease management.

Localized drug delivery to the colon allows for higher drug concentrations at the site of inflammation while minimizing systemic exposure. This is particularly beneficial for drugs with narrow therapeutic indices or significant systemic toxicity. By targeting the colon, it is possible to enhance the therapeutic effect while reducing the overall dose required, thereby improving the safety profile of the treatment.

### 1.4 Advantages of Targeted Drug Delivery

Targeted drug delivery systems are designed to overcome the limitations of conventional therapy by ensuring that the drug is released specifically at the site of disease. In the context of IBD, colon-specific drug delivery offers several advantages:

**1. Inhence Therapeutic Activity:**

By delivering the drug directly to the inflamed mucosa, higher local drug concentrations can be achieved. This leads to more effective suppression of inflammation and faster symptom relief.

**2. Reduction in systemic side effect:**

Since the drug is not widely distributed throughout the body, systemic exposure is minimized. This significantly reduces the risk of adverse effects associated with long-term therapy.

**3. Lower Dose Requirement:**

Targeted delivery allows for the use of smaller doses to achieve the desired therapeutic effect, which further enhances safety and cost-effectiveness.

**4. Improve Patient Compliance:**

Reduced dosing frequency and fewer side effects contribute to better adherence to treatment regimens, which is crucial in chronic conditions like IBD.

**5. Protection of Drug from Degradation:**

Targeted delivery systems can protect drugs from the harsh conditions of the upper GI tract, such as acidic pH and enzymatic degradation, ensuring that an adequate amount of drug reaches the colon.

**1.5 Challenges in Achieving Targeted Delivery**

Despite its advantages, achieving effective colon-specific drug delivery is challenging due to the complex and dynamic nature of the GI tract. The GI tract presents several physiological barriers that must be overcome:

- **Variable pH Conditions:** The pH of the GI tract varies significantly, from acidic in the stomach (pH 1–3) to neutral or slightly alkaline in the intestine and colon (pH 6–7.5). This variability can affect drug release from pH-sensitive systems.

- **Gastrointestinal Transit Time:** The time taken for a drug to travel through the GI tract varies among individuals and can be influenced by factors such as food intake, disease state, and motility disorders. This makes it difficult to predict the exact location and timing of drug release.

- **Enzymatic Degradation:** Digestive enzymes present in the stomach and small intestine can degrade drugs, especially peptides and proteins, before they reach the colon.

- **Mucosal Barrier:** The thick mucus layer in the colon acts as a protective barrier, limiting drug penetration to the underlying epithelial cells where inflammation occurs.

- **Microbial Variability:** The composition of colonic microbiota varies among individuals and can be altered in disease conditions, affecting the performance of microbially triggered drug delivery systems.

**1.6 Role of Colon-Specific Drug Delivery Systems**

To address these challenges, various colon-targeted drug delivery systems have been developed. These systems are designed to exploit specific physiological features of the colon, such as pH changes, transit time, and microbial activity, to achieve site-specific drug release.

For example, pH-dependent systems use polymers that dissolve at higher pH levels, ensuring that the drug is released in the intestine or colon. Time-dependent systems rely on delayed release mechanisms, while microbially triggered systems utilize the enzymatic activity of colonic bacteria to degrade carrier materials and release the drug.

These approaches have shown promise, but they are often associated with variability and lack of precision. This has led to the development of more advanced strategies, including nanotechnology-based drug delivery systems, which offer improved targeting, controlled release, and enhanced drug stability.

**Clinical Significance**

The need for targeted drug delivery in IBD is not only a scientific challenge but also a clinical necessity. Effective disease management requires maintaining therapeutic drug levels at the site of inflammation while minimizing systemic toxicity. Targeted delivery systems can significantly improve treatment outcomes by addressing these requirements.

Moreover, with the increasing prevalence of IBD and the chronic nature of the disease, there is a growing demand for therapies that are not only effective but also safe and patient-friendly. Colon-specific drug delivery systems have the potential to meet these demands by providing a more precise and efficient approach to treatment. the limitations of conventional pharmacotherapy in IBD, including systemic side effects, poor targeting, and drug instability, underscore the need for targeted drug delivery systems. The colon, being the primary site of inflammation, represents an ideal target for localized therapy. Colon-specific drug delivery systems offer significant advantages in terms of efficacy, safety, and patient compliance. However, challenges related to GI physiology and variability must be carefully addressed. Continued research and innovation in this field, particularly with the integration of nanotechnology, hold great promise for improving the management of IBD and enhancing patient outcomes.

**1.7 Challenges in Oral Colon-Specific Drug Delivery**

Oral colon-specific drug delivery systems are designed to deliver therapeutic agents directly to the colon, which is particularly beneficial in the management of conditions such as Crohn's disease and ulcerative colitis. Although these systems offer significant advantages in terms of targeted therapy and reduced systemic side effects, their development and clinical application are associated with multiple challenges. These challenges arise primarily due to the complex and highly variable physiological environment of the gastrointestinal (GI) tract.

**Table 4: Challenges in Colon-Specific Drug Delivery**

| Challenge | Description | Impact |
|---|---|---|
| pH variability | Different pH levels in GI tract | Premature drug release |
| Transit time variability | Variable GI motility | Unpredictable delivery |
| Enzymatic degradation | Drug breakdown in stomach/intestine | Reduced drug availability |
| Mucus barrier | Thick mucus layer | Poor drug penetration |
| Microflora variability | Altered gut bacteria | Inconsistent drug activation |

**1. Variability in Gastrointestinal pH**

One of the most critical challenges in oral colon-targeted drug delivery is the variation in pH along the GI tract. The stomach has a highly acidic environment (pH 1–3), which transitions to a near-neutral pH in the small intestine (pH 6–7), and becomes slightly alkaline in the colon (pH 6.5–7.5). Many colon-specific drug delivery systems, especially pH-dependent formulations, rely on these pH differences to trigger drug release.

However, this pH gradient is not constant and can vary significantly among individuals and even within the same individual under different conditions. Factors such as diet, age, disease state, and concurrent medications (e.g., proton pump inhibitors) can alter GI pH. In patients with IBD, the colonic pH may be lower than normal due to inflammation, leading to premature or incomplete drug release. As a result, pH-dependent systems may fail to deliver drugs accurately to the colon, reducing therapeutic efficacy.

**2. Unpredictable Gastrointestinal Transit Time**

Another major challenge is the variability in GI transit time, which refers to the time taken for a dosage form to travel through the digestive tract. Time-dependent drug delivery systems are designed based on an assumed transit time, with the expectation that the drug will be released after reaching the colon.

However, transit time can vary widely between individuals due to factors such as age, diet, physical activity, stress, and disease conditions. For instance, patients with diarrhea-predominant IBD may have a faster transit time, leading to premature drug release before reaching the colon. Conversely, conditions like constipation can delay drug arrival, affecting the timing and location of drug release. This unpredictability makes time-dependent systems less reliable for consistent colon targeting.

**3. Enzymatic and Chemical Degradation**

The GI tract contains a variety of digestive enzymes, including proteases, lipases, and amylases, as well as bile salts that facilitate digestion. These components can degrade drugs, especially sensitive molecules such as peptides, proteins, and certain small-molecule drugs, before they reach the colon.

For example, protein-based drugs used in IBD therapy are highly susceptible to enzymatic degradation in the stomach and small intestine. This reduces the amount of active drug available for therapeutic action in the colon. Additionally, the acidic environment

of the stomach can cause chemical degradation or denaturation of certain drugs. Protecting drugs from these harsh conditions remains a significant challenge in oral drug delivery.

**4. Mucosal and Epithelial Barriers**

Once the drug reaches the colon, it must penetrate the mucus layer and cross the epithelial barrier to exert its therapeutic effect. The colon is lined with a thick mucus layer that serves as a protective barrier against pathogens and mechanical damage. While this barrier is essential for maintaining intestinal health, it also limits the penetration of drug molecules.

The epithelial cells beneath the mucus layer are tightly joined by structures known as tight junctions, which restrict the passage of substances. This barrier function can hinder drug absorption, particularly for large or hydrophilic molecules. In inflammatory conditions like IBD, the mucus layer may become thicker or altered in composition, further complicating drug delivery.

**5. Variability in Colonic Microflora**

The colon is home to a diverse and dense population of microorganisms, collectively known as gut microbiota. These microbes play a crucial role in the activation of certain colon-targeted drug delivery systems, particularly microbially triggered systems. These systems use biodegradable polymers that are broken down by bacterial enzymes, releasing the drug in the colon.

However, the composition and activity of colonic microflora can vary significantly among individuals and can be influenced by factors such as diet, antibiotic use, age, and disease state. In IBD patients, dysbiosis (imbalance in gut microbiota) is common, which may reduce the enzymatic activity required for drug release. This variability can lead to inconsistent drug release and reduced therapeutic effectiveness.

**6. Disease-Related Changes in GI Physiology**

In conditions like Crohn's disease and ulcerative colitis, the normal physiology of the GI tract is altered. Inflammation can affect pH levels, mucus production, motility, and permeability of the intestinal lining. These changes can interfere with the performance of colon-specific drug delivery systems.

For example, increased intestinal permeability ("leaky gut") may enhance drug absorption in unintended regions, while inflammation-induced changes in motility can alter transit time. Such disease-specific variations make it difficult to design universally effective drug delivery systems.

Oral colon-specific drug delivery faces several significant challenges due to the complex and variable environment of the GI tract. Factors such as pH variability, unpredictable transit time, enzymatic degradation, mucosal barriers, and microbial diversity can all impact the effectiveness of these systems. Additionally, disease-related changes in GI physiology further complicate drug delivery in IBD patients. Overcoming these challenges requires the development of advanced and adaptable drug delivery strategies, such as nanotechnology-based systems, which can respond to multiple physiological triggers and provide more precise and reliable drug targeting to the colon.

**1.8 Conventional Approaches to Colon-Specific Drug Delivery**

Several conventional strategies have been developed to achieve colon-specific drug delivery:

**1. pH-Dependent Systems**

These systems utilize pH-sensitive polymers that remain intact in the acidic environment of the stomach and dissolve in the higher pH of the intestine or colon. Commonly used polymers include Eudragit coatings. Although widely used, these systems may suffer from variability in GI pH, especially in diseased conditions.

**2. Time-Dependent Systems**

Time-controlled systems rely on the predictable transit time of dosage forms through the GI tract. Drug release is delayed for a specific period, allowing the formulation to reach the colon before releasing the drug. However, variations in gastric emptying time and intestinal motility can lead to inconsistent drug delivery.

**3. Microbially Triggered Systems**

These systems exploit the metabolic activity of colonic bacteria to degrade specific polymers or prodrugs, thereby releasing the drug in the colon. Polysaccharides such as pectin, chitosan, and guar gum are commonly used. While promising, these systems depend heavily on the composition and activity of gut microbiota.

**4. Prodrug Approach**

In this approach, the active drug is chemically modified into an inactive prodrug that is converted into its active form by colonic enzymes. This method enhances drug stability and targeting but requires precise chemical design.

**1.9 Limitations of Conventional Systems**

Although conventional colon-targeted systems have shown some success, they are often limited by lack of precision, premature drug release, and inter-individual variability. These limitations highlight the need for more advanced and reliable drug delivery strategies that can overcome physiological barriers and ensure consistent drug delivery to the colon.

**1.10 Emergence of Nanotechnology in Drug Delivery**

Nanotechnology has emerged as a promising approach to address the limitations of conventional drug delivery systems. Nanocarriers, typically ranging in size from 1 to 1000 nm, offer unique advantages such as high surface area, enhanced permeability, and the ability to encapsulate a wide range of therapeutic agents.

Various nanocarrier systems have been explored for colon-specific drug delivery, including nanoparticles, liposomes, dendrimers, solid lipid nanoparticles, and polymeric micelles. These systems can protect drugs from degradation in the upper GI tract, enhance mucosal adhesion, and facilitate targeted drug delivery to inflamed tissues.

**1.11 Advantages of Nanotechnology-Based Systems in IBD**

Nanotechnology-based drug delivery systems offer several advantages in the treatment of IBD:

- **Targeted Drug Delivery:** Nanocarriers can be engineered to target inflamed tissues selectively.
- **Controlled and Sustained Release:** They provide controlled drug release, maintaining therapeutic drug levels over extended periods.
- **Improved Stability:** Encapsulation protects drugs from enzymatic and chemical degradation.
- **Enhanced Bioavailability:** Nanoparticles improve drug solubility and absorption.
- **Reduced Side Effects:** Targeted delivery minimizes systemic exposure and adverse effects.

Additionally, nanocarriers can be functionalized with ligands or antibodies to achieve active targeting, further enhancing therapeutic efficacy.

**1.12 Recent Advances and Hybrid Systems**

Recent research has focused on the development of hybrid systems that combine conventional and nanotechnological approaches. For example, nanoparticles can be encapsulated within pH-sensitive coatings or embedded in biodegradable matrices to achieve dual-triggered drug release. These systems offer improved specificity and reliability compared to single-mechanism systems.

Stimuli-responsive nanocarriers that respond to environmental triggers such as pH, enzymes, reactive oxygen species, and inflammatory markers are also being активно explored. These smart systems can release drugs selectively at the site of inflammation, providing a highly targeted therapeutic approach.

### 1.13 Future Perspectives

Despite significant advancements, several challenges remain in the clinical translation of nanotechnology-based colon-specific drug delivery systems. Issues such as large-scale manufacturing, regulatory approval, long-term safety, and cost-effectiveness need to be addressed. Moreover, a deeper understanding of disease pathology and patient-specific factors is essential for the development of personalized drug delivery systems.

Future research should focus on the integration of nanotechnology with advanced diagnostic tools, such as biosensors and imaging techniques, to enable real-time monitoring of drug delivery and therapeutic response. The development of multifunctional nanocarriers capable of simultaneous drug delivery and disease diagnosis (theranostics) holds great promise for the management of IBD.

### 1.14 Conclusion

Oral colon-specific drug delivery represents a crucial advancement in the effective management of Inflammatory Bowel Disease (IBD), including Crohn's disease and ulcerative colitis. Given that the colon is the primary site of inflammation in these conditions, the development of targeted drug delivery systems has gained significant importance in improving therapeutic outcomes while minimizing systemic toxicity.Conventional drug delivery approaches, although widely used, are often limited by non-specific distribution, premature drug release, and degradation of drugs in the upper gastrointestinal tract. These limitations not only reduce the therapeutic efficacy but also increase the risk of adverse effects, particularly with long-term treatment. Colon-specific drug delivery systems, including pH-dependent, time-dependent, and microbially triggered approaches, have addressed some of these issues by enabling localized drug release. However, their effectiveness is often compromised by physiological variability in gastrointestinal pH, transit time, enzyme activity, and microbial composition. In this context, nanotechnology-based drug delivery systems have emerged as a promising and innovative strategy to overcome the limitations of conventional methods. Nanocarriers such as nanoparticles, liposomes, dendrimers, and polymeric micelles offer several advantages, including enhanced drug stability, controlled and sustained release, improved mucosal penetration, and the ability to achieve site-specific targeting. Furthermore, the development of stimuli-responsive and hybrid systems that combine multiple targeting mechanisms has further improved the precision and reliability of drug delivery to the colon.

Despite these advancements, several challenges remain in the clinical translation of these technologies. Issues related to large-scale manufacturing, regulatory approval, long-term safety, and cost-effectiveness need to be carefully addressed. Additionally, inter-individual variability and disease-specific changes in gastrointestinal physiology continue to pose challenges in achieving consistent drug delivery.

In conclusion, the integration of conventional colon-targeting strategies with advanced nanotechnological approaches holds great potential for the future of IBD therapy. Continued research focusing on personalized medicine, smart drug delivery systems, and better understanding of disease pathology is essential for the development of more effective and patient-friendly treatments. Such innovations are expected to significantly enhance therapeutic efficacy, reduce adverse effects, and ultimately improve the quality of life for patients suffering from IBD.

### REFERENCES

1. Podolsky DK. Inflammatory bowel disease. *N Engl J Med*. 2002;347(6):417–429.
2. Xavier RJ, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease. *Nature*. 2007;448:427–434.
3. Hanauer SB. Inflammatory bowel disease: epidemiology and pathogenesis. *Inflamm Bowel Dis*. 2006;12:S3–S9.
4. Neurath MF. Cytokines in inflammatory bowel disease. *Nat Rev Immunol*. 2014;14:329–342.
5. Sartor RB. Microbial influences in IBD. *Gastroenterology*. 2008;134:577–594.
6. Abraham C, Cho JH. Inflammatory bowel disease. *N Engl J Med*. 2009;361:2066–2078.
7. Danese S, Fiocchi C. Ulcerative colitis. *N Engl J Med*. 2011;365:1713–1725.
8. Baumgart DC, Sandborn WJ. Crohn's disease. *Lancet*. 2012;380:1590–1605.
9. Friend DR. Colon-specific drug delivery. *Adv Drug Deliv Rev*. 1991;7:149–199.
10. Chourasia MK, Jain SK. Colon targeted drug delivery systems. *J Pharm Pharm Sci*. 2003;6:33–66.
11. Vemula SK, Veerareddy PR. Colon-specific drug delivery: review. *J Pharm Sci*. 2013;102:778–797.
12. Philip AK, Philip B. Colon targeted drug delivery systems: review. *Int J Pharm Sci Rev Res*. 2010;2:45–60.
13. Amidon S et al. Mechanistic approaches for colon delivery. *Pharm Res*. 2015;32:489–503.
14. Patel MM. Colon targeting approaches. *Expert Opin Drug Deliv*. 2011;8:1347–1362.
15. Hua S. Oral drug delivery advances. *Drug Dev Ind Pharm*. 2019;45:721–729.
16. Lamprecht A. Nanomedicine in IBD. *Int J Nanomedicine*. 2015;10:2519–2533.

17. Zhang S et al. Nanoparticles in IBD. *J Control Release*. 2017;263:276–288.
18. Liu L et al. Targeted delivery in IBD. *J Drug Target*. 2020;28:225–244.
19. D'Haens G et al. Crohn's disease therapy. *Lancet*. 2008;371:660–667.
20. Khor B et al. Genetics of IBD. *Nature*. 2011;474:307–317.
21. Ananthakrishnan AN. Environmental risk factors for IBD. *Gastroenterology*. 2015;148:284–294.
22. Torres J et al. Crohn's disease review. *Lancet*. 2017;389:1741–1755.
23. Ungaro R et al. Ulcerative colitis review. *Lancet*. 2017;389:1756–1770.
24. Allen PB et al. Biologic therapy in IBD. *BMJ*. 2020;369:m1710.
25. Sinha VR, Kumria R. Polysaccharides in colon targeting. *Int J Pharm*. 2001;224:19–38.
26. Maroni A et al. Oral colon delivery systems. *Adv Drug Deliv Rev*. 2012;64:540–556.
27. Kaur G et al. Nanotechnology in colon delivery. *Eur J Pharm Sci*. 2021;159:105715.
28. Zhao Y et al. Smart nanocarriers in IBD. *Acta Pharm Sin B*. 2022;12:450–466.

How to cite this article:
Miss. Sheetal Singh et al. Ijppr.Human, 2026; Vol. 32 (4): 178-186.

Conflict of Interest Statement: All authors have nothing else to disclose.